Product Name: Mitiglinide calcium CAS NO:145525-41-3
(aS,3aR,7aS)-Octahydro-g-oxo-a-(phenylmethyl)-2H-isoindole-2-butanoic acid calcium salt;
[2(S)-cis]-Octahydro-g-oxo-a-(phenylmethyl)-2H-isoindole-2-butanoic acid calclium salt;
Mitiglinide hemicalcium salt;
Chemical & Physical Properties:
Appearance : white to off-white powder
Boiling Point:519.6℃ at 760 mmHg
Flash Point: 268℃
Mitiglinide calcium is the third glinide hypoglycemic agent after repaglinide and nateglinide. It was successfully developed by Japan Kisei Pharmaceutical Co., Ltd. (Kissei) and was acquired by Japan on January 29, 2004. Approved by the Ministry of Health and Welfare, it was first launched in Japan in May 2004 for the treatment of type 2 diabetes. It is used as a first-line treatment for patients with early and mild to severe type 2 diabetes, and has the reputation of "in vitro pancreatic islets". Clinical trials have shown that this class of drugs is superior to other hypoglycemic drugs in terms of efficacy and safety so far. It is a new type of fast-acting "meal blood glucose regulator" that promotes insulin secretion by pancreatic islet cells. It is suitable for diet and exercise therapy. Patients with type 2 diabetes who can effectively control hyperglycemia are mainly used to control postprandial hyperglycemia.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.